Advanced delivery of natural bioactive compounds for atopic dermatitis: a review of polymeric conjugates and nanocarriers.

Nat Prod Bioprospect · 2026 · PMC12873061 · PMID 41639533

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The first biologic approved for use by FDA and EMA is dupilumab, which blocks IL-4 and IL-13 by blocking IL-4Ra, reaching highly significant suppression of inflammation and pruritus with a very good safety profile.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.